Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
81.96 USD | -0.88% | -0.24% | +14.71% |
09-05 | Transcript : Hologic, Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-05-2024 12:20 PM | |
08-02 | Stephens Raises Hologic's Price Target to $95 From $92 | MT |
Fiscal Period: September | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Revenues | 3.37B | 3.78B | 5.63B | 4.86B | 4.03B | |||||
Total Revenues | 3.37B | 3.78B | 5.63B | 4.86B | 4.03B | |||||
Cost of Goods Sold, Total | 1.29B | 1.26B | 1.56B | 1.55B | 1.55B | |||||
Gross Profit | 2.08B | 2.51B | 4.07B | 3.31B | 2.48B | |||||
Selling General & Admin Expenses, Total | 885M | 844M | 972M | 1.04B | 995M | |||||
R&D Expenses | 232M | 222M | 276M | 283M | 294M | |||||
Amortization of Goodwill and Intangible Assets - (IS) | 370M | 293M | 319M | 341M | 234M | |||||
Other Operating Expenses | - | -2.9M | 22.7M | - | - | |||||
Other Operating Expenses, Total | 1.49B | 1.36B | 1.59B | 1.66B | 1.52B | |||||
Operating Income | 588M | 1.16B | 2.49B | 1.65B | 958M | |||||
Interest Expense, Total | -141M | -116M | -93.6M | -95.1M | -111M | |||||
Interest And Investment Income | 4.6M | 4.3M | 1.4M | 12.9M | 120M | |||||
Net Interest Expenses | -136M | -112M | -92.2M | -82.2M | 9.4M | |||||
Income (Loss) On Equity Invest. | -3.3M | - | - | - | - | |||||
Currency Exchange Gains (Loss) | 5.1M | 3.2M | -17.1M | 48.5M | -7.9M | |||||
Other Non Operating Income (Expenses) | 400K | 2.7M | 13.5M | -11.7M | 6.2M | |||||
EBT, Excl. Unusual Items | 454M | 1.05B | 2.39B | 1.6B | 966M | |||||
Restructuring Charges | -6.6M | -15.3M | -9.3M | -2.4M | -36.7M | |||||
Merger & Related Restructuring Charges | -7.1M | -6.8M | -2.3M | - | - | |||||
Impairment of Goodwill | - | - | - | - | - | |||||
Gain (Loss) On Sale Of Investments | 900K | 3.2M | -1.8M | -8.3M | - | |||||
Gain (Loss) On Sale Of Assets | - | - | - | - | -51.7M | |||||
Asset Writedown | -579M | -30.2M | - | -45.1M | -224M | |||||
In Process R&D Expenses | -107M | - | - | - | - | |||||
Insurance Settlements | - | - | - | 2.4M | - | |||||
Legal Settlements | -10.5M | - | - | - | 7.4M | |||||
Other Unusual Items | -2.5M | - | -14.9M | 38.8M | 14.9M | |||||
EBT, Incl. Unusual Items | -258M | 1B | 2.36B | 1.59B | 676M | |||||
Income Tax Expense | -54.1M | -109M | 491M | 286M | 220M | |||||
Earnings From Continuing Operations | -204M | 1.11B | 1.87B | 1.3B | 456M | |||||
Net Income to Company | -204M | 1.11B | 1.87B | 1.3B | 456M | |||||
Minority Interest | - | 4.7M | 1.8M | - | - | |||||
Net Income - (IS) | -204M | 1.12B | 1.87B | 1.3B | 456M | |||||
Net Income to Common Incl Extra Items | -204M | 1.12B | 1.87B | 1.3B | 456M | |||||
Net Income to Common Excl. Extra Items | -204M | 1.12B | 1.87B | 1.3B | 456M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | -0.76 | 4.24 | 7.28 | 5.18 | 1.85 | |||||
Basic EPS - Continuing Operations | -0.76 | 4.24 | 7.28 | 5.18 | 1.85 | |||||
Basic Weighted Average Shares Outstanding | 269M | 263M | 257M | 252M | 247M | |||||
Net EPS - Diluted | -0.76 | 4.21 | 7.21 | 5.13 | 1.83 | |||||
Diluted EPS - Continuing Operations | -0.76 | 4.21 | 7.21 | 5.13 | 1.83 | |||||
Diluted Weighted Average Shares Outstanding | 269M | 265M | 260M | 254M | 249M | |||||
Normalized Basic EPS | 1.05 | 2.52 | 5.82 | 3.98 | 2.45 | |||||
Normalized Diluted EPS | 1.05 | 2.5 | 5.76 | 3.95 | 2.43 | |||||
American Depositary Receipts Ratio (ADR) | 1 | 1 | 1 | 1 | 1 | |||||
Supplemental Items | ||||||||||
EBITDA | 1.05B | 1.53B | 2.89B | 2.08B | 1.28B | |||||
EBITA | 958M | 1.45B | 2.8B | 1.99B | 1.19B | |||||
EBIT | 588M | 1.16B | 2.49B | 1.65B | 958M | |||||
EBITDAR | 1.07B | 1.56B | 2.92B | 2.11B | 1.31B | |||||
Total Revenues (As Reported) | 3.37B | 3.78B | 5.63B | 4.86B | 4.03B | |||||
Effective Tax Rate - (Ratio) | 20.99 | -10.84 | 20.81 | 18.02 | 32.55 | |||||
Current Domestic Taxes | 165M | -28.2M | 538M | 353M | 296M | |||||
Current Foreign Taxes | 16.5M | 14M | 23.2M | 99M | 32.7M | |||||
Total Current Taxes | 182M | -14.2M | 562M | 452M | 329M | |||||
Deferred Domestic Taxes | -231M | -89.1M | -57.5M | -139M | -81.5M | |||||
Deferred Foreign Taxes | -4.7M | -5.3M | -12.6M | -26.9M | -27.6M | |||||
Total Deferred Taxes | -236M | -94.4M | -70.1M | -166M | -109M | |||||
Normalized Net Income | 283M | 662M | 1.5B | 1B | 604M | |||||
Interest on Long-Term Debt | 141M | 116M | 93.6M | 95.1M | 111M | |||||
Non-Cash Pension Expense | 300K | 300K | 400K | 4M | 3.9M | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | 29.5M | 15.6M | 9.8M | 78.1M | 31.4M | |||||
Selling and Marketing Expenses | 565M | 485M | 561M | 630M | 595M | |||||
General and Administrative Expenses | 320M | 359M | 410M | 408M | 400M | |||||
Research And Development Expense From Footnotes | 1.13B | 483M | 564M | 596M | 680M | |||||
Net Rental Expense, Total | 23.1M | 27.5M | 30.1M | 28.6M | 29.9M | |||||
Imputed Operating Lease Interest Expense | 8.04M | 8.16M | 7.13M | 7.15M | 9.12M | |||||
Imputed Operating Lease Depreciation | 15.06M | 19.34M | 22.97M | 21.45M | 20.78M | |||||
Stock-Based Comp., COGS (Total) | 7.1M | 6.7M | 8M | 9.1M | 10.5M | |||||
Stock-Based Comp., R&D Exp. (Total) | 9.2M | 8M | 7.7M | 8.8M | 10.5M | |||||
Stock-Based Comp., S&M Exp. (Total) | 10.2M | 10.2M | 9.5M | 10.5M | 12M | |||||
Stock-Based Comp., G&A Exp. (Total) | 35.5M | 50.9M | 38.9M | 38.3M | 46.6M | |||||
Stock-Based Comp., Other (Total) | - | 7.5M | 900K | - | - | |||||
Total Stock-Based Compensation | 62M | 83.3M | 65M | 66.7M | 79.6M |